141 related articles for article (PubMed ID: 26108486)
1. CYP11A1 expression in bone is associated with aromatase inhibitor-related bone loss.
Rodríguez-Sanz M; García-Giralt N; Prieto-Alhambra D; Servitja S; Balcells S; Pecorelli R; Díez-Pérez A; Grinberg D; Tusquets I; Nogués X
J Mol Endocrinol; 2015 Aug; 55(1):69-79. PubMed ID: 26108486
[TBL] [Abstract][Full Text] [Related]
2. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
[TBL] [Abstract][Full Text] [Related]
3. AI-related BMD variation in actual practice conditions: A prospective cohort study.
Rodríguez-Sanz M; Prieto-Alhambra D; Servitja S; Garcia-Giralt N; Garrigos L; Rodriguez-Morera J; Albanell J; Martínez-García M; González I; Diez-Perez A; Tusquets I; Nogués X
Endocr Relat Cancer; 2016 Apr; 23(4):303-12. PubMed ID: 26911377
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.
Napoli N; Rastelli A; Ma C; Yarramaneni J; Vattikutti S; Moskowitz G; Giri T; Mueller C; Kulkarny V; Qualls C; Ellis M; Armamento-Villareal R
Bone; 2013 Aug; 55(2):309-14. PubMed ID: 23643682
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer.
Napoli N; Rastelli A; Ma C; Colleluori G; Vattikuti S; Armamento-Villareal R
Pharmacogenet Genomics; 2015 Aug; 25(8):377-81. PubMed ID: 26049585
[TBL] [Abstract][Full Text] [Related]
7. Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer.
Servitja S; Nogués X; Prieto-Alhambra D; Martínez-García M; Garrigós L; Peña MJ; de Ramon M; Díez-Pérez A; Albanell J; Tusquets I
Breast; 2012 Feb; 21(1):95-101. PubMed ID: 21924904
[TBL] [Abstract][Full Text] [Related]
8. Significant association between common polymorphisms in the aromatase gene CYP19A1 and bone mineral density in postmenopausal women.
Mullin BH; Carter KW; Lewis JR; Ingley E; Wilson SG; Prince RL
Calcif Tissue Int; 2011 Dec; 89(6):464-71. PubMed ID: 21952832
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
10. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
11. [Effect of aromatase inhibitors on bone metabolism].
Folkestad L; Bjerregaard JK; Bjarnason NH; Brixen KT
Ugeskr Laeger; 2007 May; 169(19):1774-9. PubMed ID: 17537350
[TBL] [Abstract][Full Text] [Related]
12. CYP19A1 rs10046 Pharmacogenetics in Postmenopausal Breast Cancer Patients Treated with Aromatase Inhibitors: One-year Follow-up.
Baatjes K; Peeters A; McCaul M; Conradie MM; Apffelstaedt J; Conradie M; Kotze MJ
Curr Pharm Des; 2020; 26(46):6007-6012. PubMed ID: 32900345
[TBL] [Abstract][Full Text] [Related]
13. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
[TBL] [Abstract][Full Text] [Related]
14. Markers of bone metabolism in women receiving aromatase inhibitors for early-stage breast cancer.
Barginear M; Clotfelter A; Poznak CV
Clin Breast Cancer; 2009 May; 9(2):72-6. PubMed ID: 19433386
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
16. The effect of aromatase inhibitors on bone metabolism.
Folkestad L; Bjarnason NH; Bjerregaard JK; Brixen K
Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):3-10. PubMed ID: 19152547
[TBL] [Abstract][Full Text] [Related]
17. The rs4844880 polymorphism in the promoter region of the HSD11B1 gene associates with bone mineral density in healthy and postmenopausal osteoporotic women.
Feldman K; Szappanos A; Butz H; Grolmusz V; Majnik J; Likó I; Kriszt B; Lakatos P; Tóth M; Rácz K; Patócs A
Steroids; 2012 Nov; 77(13):1345-51. PubMed ID: 22986073
[TBL] [Abstract][Full Text] [Related]
18. Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.
Oyan B
Med Hypotheses; 2011 Dec; 77(6):1028-30. PubMed ID: 21930348
[TBL] [Abstract][Full Text] [Related]
19. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
20. Bone health evaluation one year after aromatase inhibitors completion.
Pineda-Moncusí M; Servitja S; Casamayor G; Cos ML; Rial A; Rodriguez-Morera J; Tusquets I; Diez-Perez A; Garcia-Giralt N; Nogués X
Bone; 2018 Dec; 117():54-59. PubMed ID: 30223134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
